Literature DB >> 19008719

Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism.

Giampaolo Bernini1, Fabio Galetta, Ferdinando Franzoni, Michele Bardini, Chiara Taurino, Melania Bernardini, Lorenzo Ghiadoni, Matteo Bernini, Gino Santoro, Antonio Salvetti.   

Abstract

OBJECTIVES: To evaluate vascular wall structure and conduit artery stiffness in patients with primary aldosteronism.
METHODS: This observational study, conducted in a University Hypertension Center, evaluated the carotid wall by 2-D ultrasonography and ultrasonic tissue characterization, and analyzed arterial stiffness by applanation tonometer. Twenty-three consecutive patients with primary aldosteronism, 24 matched patients with essential hypertension and 15 controls were studied. Intima-media thickness and corrected integrated backscatter signal of the carotid arteries were evaluated. Radial and femoral pulse wave velocity and aortic augmentation index were also investigated.
RESULTS: Intima-media thickness in patients with essential hypertension (0.69 +/- 0.03 mm) was higher (P < 0.04) than that in controls (0.59 +/- 0.02 mm). This finding was more evident in primary aldosteronism patients (0.84 +/- 0.03 mm), in whom intima-media thickness was greater than that in controls (P < 0.0001) or in patients with essential hypertension (P < 0.01). Similarly, corrected integrated backscatter signal in patients with essential hypertension (-23.6 +/- 0.35 dB) was higher (P < 0.0001) than that in controls (-26.2 +/- 0.44 dB), but it was even more elevated in patients with primary aldosteronism (-22.1 +/- 0.46 dB), who showed greater corrected integrated backscatter signal than was the case in patients with essential hypertension (P < 0.009) or in controls (P < 0.0001). Femoral pulse wave velocity was higher in primary aldosteronism patients (10.8 +/- 0.57 m/s) than in patients with essential hypertension (9.1 +/- 0.34 m/s, P < 0.03) or in controls (7.1 +/- 0.51 m/s, P < 0.0001). Femoral pulse wave velocity was lower in controls than in patients with essential hypertension (P < 0.0001). The same pattern was observed for radial pulse wave velocity. Aortic augmentation index was higher in primary aldosteronism patients (28.2 +/- 2.1%) than in patients with essential hypertension (26.0 +/- 1.8%) or in controls (16.8 +/- 2.0%, P < 0.001). Patients with essential hypertension likewise exhibited higher aortic augmentation index than controls (P < 0.001).
CONCLUSION: Aldosterone excess is responsible per se for vascular morphological (wall thickening and carotid artery fibrosis) and functional (central stiffness) damage.

Entities:  

Mesh:

Year:  2008        PMID: 19008719     DOI: 10.1097/HJH.0b013e32831286fd

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  37 in total

1.  Serum aldosterone is associated with inflammation and aortic stiffness in normotensive overweight and obese young adults.

Authors:  Jennifer N Cooper; Ping Tepper; Emma Barinas-Mitchell; Genevieve A Woodard; Kim Sutton-Tyrrell
Journal:  Clin Exp Hypertens       Date:  2011-10-18       Impact factor: 1.749

Review 2.  Endocrine Tumors Causing Arterial Hypertension: Pathophysiological Mechanisms and Clinical Implications.

Authors:  Agata Buonacera; Benedetta Stancanelli; Lorenzo Malatino
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-04-12

3.  Alterations in vascular function in primary aldosteronism: a cardiovascular magnetic resonance imaging study.

Authors:  P B Mark; S Boyle; L U Zimmerli; E P McQuarrie; C Delles; E M Freel
Journal:  J Hum Hypertens       Date:  2013-07-25       Impact factor: 3.012

Review 4.  Mineralocorticoid receptors in vascular function and disease.

Authors:  Amy McCurley; Iris Z Jaffe
Journal:  Mol Cell Endocrinol       Date:  2011-06-24       Impact factor: 4.102

5.  Mineralocorticoid receptor antagonism protects the aorta from vascular smooth muscle cell proliferation and collagen deposition in a rat model of adrenal aldosterone-producing adenoma.

Authors:  Yongji Yan; Chao Wang; Yiqin Lu; Huijie Gong; Zhun Wu; Xin Ma; Hongzhao Li; Baojun Wang; Xu Zhang
Journal:  J Physiol Biochem       Date:  2017-11-21       Impact factor: 4.158

6.  Aldosterone, inactive matrix gla-protein, and large artery stiffness in hypertension.

Authors:  Julio A Chirinos; Mayank Sardana; Amer Ahmed Syed; Maheshwara R Koppula; Swapna Varakantam; Izzah Vasim; Harold G Oldland; Timothy S Phan; Nadja E A Drummen; Cees Vermeer; Raymond R Townsend; Scott R Akers; Wen Wei; Edward G Lakatta; Olga V Fedorova
Journal:  J Am Soc Hypertens       Date:  2018-06-30

7.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

Review 8.  Vascular Smooth Muscle Remodeling in Conductive and Resistance Arteries in Hypertension.

Authors:  Isola A M Brown; Lukas Diederich; Miranda E Good; Leon J DeLalio; Sara A Murphy; Miriam M Cortese-Krott; Jennifer L Hall; Thu H Le; Brant E Isakson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-09       Impact factor: 8.311

Review 9.  Diagnosing and Managing Primary Aldosteronism in Hypertensive Patients: a Case-Based Approach.

Authors:  Robert M Carey
Journal:  Curr Cardiol Rep       Date:  2016-10       Impact factor: 2.931

10.  Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness.

Authors:  Anne Pizard; Alexandre Gueret; Guillaume Galmiche; Soumaya El Moghrabi; Antoine Ouvrard-Pascaud; Stefan Berger; Pascal Challande; Iris Z Jaffe; Carlos Labat; Patrick Lacolley; Frédéric Jaisser
Journal:  Hypertension       Date:  2013-12-02       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.